Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1996 1
1997 1
2001 1
2002 1
2008 1
2009 1
2010 1
2019 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation.
Kvarnhammar AM, Veitonmäki N, Hägerbrand K, Dahlman A, Smith KE, Fritzell S, von Schantz L, Thagesson M, Werchau D, Smedenfors K, Johansson M, Rosén A, Åberg I, Winnerstam M, Nyblom E, Barchan K, Furebring C, Norlén P, Ellmark P. Kvarnhammar AM, et al. Among authors: barchan k. J Immunother Cancer. 2019 Apr 11;7(1):103. doi: 10.1186/s40425-019-0570-8. J Immunother Cancer. 2019. PMID: 30975201 Free PMC article.
ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1.
Enell Smith K, Fritzell S, Nilsson A, Barchan K, Rosén A, Schultz L, Varas L, Säll A, Rose N, Håkansson M, von Schantz L, Ellmark P. Enell Smith K, et al. Among authors: barchan k. Cancer Immunol Immunother. 2023 Dec;72(12):4145-4159. doi: 10.1007/s00262-023-03548-7. Epub 2023 Oct 5. Cancer Immunol Immunother. 2023. PMID: 37796298 Free PMC article.
Directed evolution of chemotaxis inhibitory protein of Staphylococcus aureus generates biologically functional variants with reduced interaction with human antibodies.
Gustafsson E, Rosén A, Barchan K, van Kessel KP, Haraldsson K, Lindman S, Forsberg C, Ljung L, Bryder K, Walse B, Haas PJ, van Strijp JA, Furebring C. Gustafsson E, et al. Among authors: barchan k. Protein Eng Des Sel. 2010 Feb;23(2):91-101. doi: 10.1093/protein/gzp062. Epub 2009 Dec 3. Protein Eng Des Sel. 2010. PMID: 19959567
Development of interleukin-1 receptor antagonist mutants with enhanced antagonistic activity in vitro and improved therapeutic efficacy in collagen-induced arthritis.
Dahlén E, Barchan K, Herrlander D, Höjman P, Karlsson M, Ljung L, Andersson M, Bäckman E, Hager AC, Walse B, Joosten L, van den Berg W. Dahlén E, et al. Among authors: barchan k. J Immunotoxicol. 2008 Apr;5(2):189-99. doi: 10.1080/15476910802131477. J Immunotoxicol. 2008. PMID: 18569390
Identification of the major proteoglycans from human myometrium.
Hjelm A, Ekman-Ordeberg G, Barchan K, Malmström A. Hjelm A, et al. Among authors: barchan k. Acta Obstet Gynecol Scand. 2001 Dec;80(12):1084-90. doi: 10.1034/j.1600-0412.2001.801202.x. Acta Obstet Gynecol Scand. 2001. PMID: 11846703 Free article.